Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lymphoma 6Breast Neoplasms 6Leukemia 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Large B-Cell, Diffuse 4Sarcoma 3Osteosarcoma 3Sarcoma, Synovial 2Sarcoma, Alveolar Soft Part 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Neurofibrosarcoma 2Liposarcoma 2Leukemia, T-Cell 2Leiomyosarcoma 2Histiocytoma, Malignant Fibrous 2Fibrosarcoma 2Fallopian Tube Neoplasms 2Chondrosarcoma, Extraskeletal Myxoid 2Triple Negative Breast Neoplasms 1Thymoma 1Thymic epithelial tumor 1The Neoadjuvant Therapy 1Sezary Syndrome 1Sarcoma, Ewing 1Sarcoma, Clear Cell 1Renal Pelvis and Ureter Urothelial Carcinoma 1Perivascular Epithelioid Cell Neoplasms 1Nerve Sheath Neoplasms 1Neoplasms, Connective and Soft Tissue 1

Interventions

Doxorubicin 1Cyclophosphamide 1Cisplatin 1Carboplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Thymic epithelial tumor × Doxorubicin × Clear all
NCT07463313 2026-03-11

6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2/3 Not yet recruiting
116 enrolled
Thoracic

Thymic epithelial tumor, Mediastinal Neoplasms, Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡